logo

THRX(Delisted)

Theseus·NASDAQ
--
--(--)

THRX Profile

Theseus Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company focused on transformative targeted therapies working to outsmart cancer resistance

--
--
10/07/2021
NASDAQ Stock Exchange
38
12-31
Common stock
245 Main Street, Cambridge, Massachusetts 02142
--
Theseus Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware in December 2017. The company is a biopharmaceutical company dedicated to improving the lives of cancer patients by discovering, developing and commercializing transformative targeted therapies. The company's development program is aimed at addressing drug-resistant mutations that are key drivers of oncogenes, which are mutant genes that cause cancer. The company's goal is to develop "pan-variant" kinase inhibitors — inhibitors of all major carcinogenic and drug-resistant mutations in clinically important protein kinases.